Kodiak Sciences reported a Phase 3 “Daybreak” success showing noninferior vision outcomes versus Regeneron’s Eylea (aflibercept) for both tarcocimab tedromer (Zenkuda) and the anti-IL-6/VEGF-trap bispecific tabirafusp-alpha-tedromer (KSI-501) in wet age-related macular degeneration. Shares surged after the results, with Kodiak signaling plans to seek FDA approval for Zenkuda. The company said Zenkuda matched Eylea while using an individualized dosing approach that allowed more than half of patients to receive injections once every six months rather than every eight weeks for Eylea. Kodiak also highlighted durability strategy implications and pointed to additional Phase 3 data sets as it moves toward potential regulatory submissions.